Protozoa belonging to the Leishmania donovani complex, including L. donovani and L. chagasi, cause the potentially fatal disease visceral leishmaniasis. Clinical and experimental studies indicate that specific cellular immune responses are required for cure of and protection against this disease. Acute visceral leishmaniasis in humans and mice is associated with high levels of both polyclonal and parasite antigen-specific antibodies which do not prevent disease progression (11, 15) . At the same time, cellular immune responses resulting in the production of gamma interferon (IFN-␥), interleukin-2 (IL-2), IL-1, and tumor necrosis factor are defective. These defects recover upon cure of the disease (6, 20, 34) . Both humans and mice develop protective immunity after recovery from visceral leishmaniasis (30, 51) . Different mouse strains are genetically resistant to infection with visceralizing Leishmania spp. (2, 17) , and spontaneous resolution of disease in susceptible strains results in resistance to rechallenge. Passive transfer studies indicate that this resistance is due to immune T-cell responses in these ''resolved'' mice (51) . Thus, an immunoprotective response to the parasite must exist. As a corollary, there must be Leishmania antigens that stimulate protective T-cell responses in immune hosts.
Although L. major primarily causes cutaneous ulcers in humans, it causes a spectrum of diseases ranging from a selfhealing ulcer to a disseminated fatal infection in different strains of mice (17) . The curative or progressive phenotype of these mice has been correlated with the expansion of one or the other of two distinct subsets of CD4 ϩ lymphocytes (18, 19, 45) . Cells which belong to the T T helper-1 (Th1) subset produce IFN-␥ and IL-2 and confer protection against L. major, whereas Th2 CD4 ϩ cells elaborate IL-4, IL-5, IL-6, IL-10, and IL-13 and exacerbate disease (19) . In contrast, a similar pattern of disease-exacerbating versus protective T-helper cell subsets has not been documented in mice infected with visceralizing strains of Leishmania (25, 47) . However, a consistent correlation has been found between (i) the production of IFN-␥ in response to antigen or mitogen and (ii) either resolution of or resistance to L. donovani infection (7, 25) . This IFN-␥ may originate from CD4 ϩ , CD8 ϩ , or natural killer cells (29, 43, 49) , all of which might be important for cure of murine or human disease (5, 24, 49) . In contrast, expression of IL-10 mRNA correlates with progression of visceral leishmaniasis (16, 23) .
The purpose of this study was to identify specific parasite antigens that stimulate T-cell responses in mice exposed to a visceralizing strain of Leishmania. Because of the relevance of IFN-␥ to recovery from visceral leishmaniasis, we chose to study L. chagasi antigens that stimulate IFN-␥ production by immune cells from mice that are either susceptible or resistant to L. chagasi disease. Such antigens would logically be found in the obligate intracellular amastigote form of leishmaniae, since this is the only form in an infected host. There are inherent difficulties in purifying proteins in sufficient quantity and purity for lymphocyte assays from intracellular amastigote forms. Thus, we selected T-cell antigens from an amastigote cDNA library by using a coupled antibody-T-cell screening technique. We identified one recombinant antigen (Lcr1) containing homologous 67-amino-acid repeats that stimulated IFN-␥ but not IL-10, IL-4, or IL-5 production by lymphocytes from both susceptible and resistant mice. Lcr1 provided partial protection against challenge with L. chagasi, indicating its potential utility in a subunit vaccine.
MATERIALS AND METHODS
Parasites and mouse models. A strain of L. chagasi originally isolated from a Brazilian patient with visceral leishmaniasis was kindly provided by Richard Pearson, University of Virginia. Parasites were maintained in hamsters, and isolated amastigotes were allowed to convert to promastigotes in a modified minimal essential medium (HOMEM) as described (36) . Promastigote cultures were maintained at 26ЊC in the same medium.
BALB/c or C3H.HeJ mice were infected by intravenous introduction of 10 7 promastigotes into a tail vein. Some BALB/c mice were immunized several times with 20 or 100 g of purified recombinant Lcr1 protein, introduced subcutaneously with Freund's (20 g) or Ribi (100 g) adjuvant (Ribi Immunochemicals, Hamilton, Mont.) prior to parasite challenge. Control mice received adjuvant in buffer alone. Parasite loads were determined from the weights and impression smears of livers and spleens after 2 to 10 weeks as described by Stauber (48) . Parasite loads are expressed as total amastigotes in each organ, calculated as (amastigote/mononuclear cell ratio) ϫ organ weight (mg) ϫ (2 ϫ 10 5 ). Shown are the mean Ϯ standard error (SE) amastigotes in livers and spleens of four mice.
Splenocyte assays. Spleens were removed from mice 2 weeks after infection with L. chagasi, and single-cell suspensions were prepared by passage through a sterile screen. B cells were removed by panning on anti-immunoglobulin G (9). According to fluorescence-activated cell sorting (FACS) analysis, such enrichment yielded a population containing 60.0% Ϯ 1.1% CD4 (32) . IL-5 was captured with TRFK5 and detected with biotinylated TRFK4 (monoclonal antibodies from DNAX) followed by streptavidin-peroxidase conjugate and ABTS peroxidase substrate (55) . The IL-10 ELISA, kindly released for our use by Kevin Moore (DNAX), used SXC-2 as the capture antibody and biotinylated SXC-1 as the secondary antibody (both from the American Type Culture Collection) (12, 13, 32) . A standard curve was prepared with recombinant IL-10, provided by Satish Menon (DNAX). The sensitivities of ELISAs were 30 pg of IFN-␥ per ml, 120 pg of IL-4 per ml, 30 pg of IL-5 per ml, and 500 pg of IL-10 per ml.
Preparation and screening of the amastigote cDNA library. Total RNA from 1.2 ϫ 10 9 amastigotes isolated from 11 infected hamster spleens was primed with oligo(dT) for cDNA synthesis, using a kit from Stratagene (La Jolla, Calif.). The cDNA library was constructed in lambda Zap II as instructed by the manufacturer (Stratagene). The library was immunoscreened with serum from Brazilian patients with visceral leishmaniasis, kindly provided by Cynthia Andrade (Recife, Brazil), followed by a secondary peroxidase conjugated anti-human immunoglobulin G and peroxidase substrate (4-Cl-1-naphthol, imidazole, H 2 O 2 ) (42). Recombinant phage were purified in a second or third immunoscreen.
Fusion proteins were prepared for T-cell assays by the method of Mustafa et al. (35) , modified for a smaller number of clones. Briefly, individual phage in SM medium were transferred to wells of a 96-well plate and used to infect Escherichia coli XL1Blue (Stratagene) in a second plate. Transformed bacteria were transferred to 0.7% LB agar containing 10 mM isopropyl-␤-D-thiogalactopyranoside (IPTG) and plated over 1.5% LB agar in wells of a third plate. After incubation at 42ЊC for 4 h, plates were incubated overnight at 37ЊC to allow expression of recombinant antigen. Wells were overlaid with RPMI 1640 containing 100 U of penicillin per ml, 100 g of streptomycin per ml, and 10 g of polymyxin B per ml and shaken for 1 h at room temperature to allow recombinant fusion proteins to diffuse into the medium. Recombinant protein-containing supernatants were incorporated into splenocyte proliferation assays at a dilution of 1:100.
Nucleic acid analyses. The Bluescript phagemid containing the Lcr1 sequence was excised from its corresponding phage clone as instructed by the manufacturer (Stratagene). The sequence of insert DNA was determined by a combination of standard dideoxy termination techniques (42) and the automated DNA sequencer at the University of Iowa DNA core facility. For Northern (RNA) blots, total RNA was extracted from L. chagasi promastigotes and amastigotes by precipitation in LiCl and urea (54) . Northern and Southern blots of restriction enzyme-digested L. chagasi genomic DNA were hybridized with 32 P-labeled purified insert DNA from the Lcr1-encoding plasmid (42) .
Purification of recombinant Lcr1. To purify Lcr1 recombinant protein, the Lcr1 sequence was subcloned into pRSET (InVitrogen, San Diego, Calif.) downstream of a T7 promoter and in frame with a fusion peptide encoding a polyhistidine metal-binding domain. E. coli JM109 cells were transformed with the plasmid, and the Lcr1 protein was expressed by coinfection of bacteria with a T7-producing phage in the presence of IPTG (InVitrogen). Recombinant Lcr1 was purified over a nickel-containing column according to the manufacturer's instructions. Rabbits were immunized with 200 g of recombinant Lcr1 and Ribi adjuvant followed by two boosts at 2-week intervals according to the manufacturer's instructions. Polyclonal anti-Lcr1 serum was used for immunoprecipitation of Lcr1 from promastigotes incubated in [ 35 S]methionine (54) . Purified Lcr1 or proteins immunoprecipitated from promastigote lysates were analyzed on sodium dodecyl sulfate (SDS)-10% polyacrylamide gels that had been subjected to Coomassie blue staining or autoradiography (26) . Proteins from promastigote or bacterial lysates were transferred to nitrocellulose and incubated in 1:500 immune mouse or human serum followed by 1:1,000 peroxidase-conjugated anti-mouse (or anti-human) immunoglobulin G, 3,3Ј-diaminobenzidine, and H 2 O 2 (Sigma) (53) .
Statistical analysis. Cytokine concentrations or parasite loads were analyzed by using the t test or paired t test with SigmaStat software (Jandel, San Rafael, Calif.).
Nucleotide sequence accession number. The GenBank accession number for Lcr1 is U23437.
RESULTS
Antibody and T-cell screening. The L. chagasi amastigote cDNA library was initially immunoscreened with serum from Brazilians with visceral leishmaniasis in order to identify large numbers of protein-producing phage clones. Such sera recognize hundreds of parasite proteins, as we have documented on two-dimensional immunoblots of parasite proteins (not shown). The library screening yielded 71 positive clones which were purified in a second or third immunoscreen.
Recombinant proteins produced by these phage were subjected to a secondary screen for the ability to cause T-cell proliferation. For most assays, we used splenic T-cell-enriched populations from BALB/c mice infected with L. chagasi and mitomycin-treated syngeneic normal splenocytes as antigenpresenting cells (14) . Positive control wells contained concanavalin A (5 g/ml) or live promastigotes (3 ϫ 10 protein not present in untransformed bacteria, detected by immunoblotting with pooled visceral leishmaniasis patient serum (Fig. 1, lanes A to C) . The 785-bp Lcr1-encoding cDNA was subcloned into pRSET and similarly caused expression of the 40-kDa protein in E. coli JM109. The recombinant Lcr1 was purified from JM109 lysates on a nickel-containing column (Fig. 1, lanes D and E) .
Splenocyte responses to purified recombinant Lcr1. The literature documents that BALB/c mice are susceptible and C3H mice are resistant to L. donovani infection (2, 17, 21) . Similarly, according to our preliminary studies, BALB/c mice were susceptible and C3H.HeJ mice were resistant to L. chagasi infection. We used these murine models to study T-cell responses to Lcr1. T-cell-enriched splenocytes from infected BALB/c mice exhibited a moderate proliferative response to the purified recombinant Lcr1, with a mean SI of 4.1 Ϯ 0.6 (n ϭ 9 experiments, each with triplicates of conditions; P Ͻ 0.001 compared with unstimulated cells). Assay of T-cell-enriched splenic cells from infected C3H.HeJ mice indicated an average SI of 2.3 Ϯ 0.4 (n ϭ 5 experiments; P Ͻ 0.05). Cultivation of T cells from the two models with either Lcr1 or live promastigotes also caused the secretion of IFN-␥. This secretion was significantly greater than spontaneous IFN-␥ release or IFN-␥ released by T cells from uninfected BALB/c mice (Fig. 2) .
T-cell-enriched splenocytes from either infected or uninfected BALB/c mice secreted IL-10 spontaneously when cultured in the presence of syngeneic antigen-presenting cells (Table 1) . Infected C3H.HeJ mouse T cells also released IL-10 spontaneously, but in lesser amounts. The amount of IL-10 increased significantly upon cultivation of T-cell-enriched cells from infected BALB/c, infected C3H, or uninfected BALB/c mice with L. chagasi promastigotes. In contrast, Lcr1 did not change the amount of IL-10 released above background (spontaneous release) levels (Table 1) (Fig. 3A) . Analysis of the deduced amino acid sequence (Fig. 3B ) revealed four nonidentical 67-amino-acid polypeptide repeats homologous to a repetitive antigen from Trypanosoma cruzi called the flagellar repeat antigen (FRA) (22, 27) . In contrast to Lcr1, the gene encoding FRA contains more than 12 exact 204-bp repeated DNA units and the protein has 68-amino-acid exact repeats. A consensus sequence derived from the four L. chagasi Lcr1 repeats represented in our cDNA clone had 49% identity with the T. cruzi FRA repeat polypeptide (Fig. 3C) . The mRNA for FRA is approximately 10 kb (27) . Similarly, the Lcr1 cDNA insert hybridized to an mRNA of greater than 10 kb on Northern blots of promastigote and amastigote RNA. Hybridization of parallel Northern blots with a [ 32 P]DNA sequence encoding ␣-and ␤-tubulin showed the expected pattern of four bands (one ␣-and three ␤-tubulin RNAs) and demonstrated equal loading of lanes (Fig. 4) (46, 54) . Southern hybridization of Lcr1 to L. chagasi genomic DNA, digested with a panel of restriction enzymes that cut either once or not at all in the cloned sequence, revealed a pattern of bands consistent with a single copy of the gene (a representative blot is shown in Fig. 5A ). One enzyme (MscI) that cuts at the 5Ј end of the first repeat in our cDNA clone revealed a complex pattern. Partial MscI digests showed a ladder of bands indicating the enzyme likely cut in more than one repeated sequence (Fig. 5B) . The lack of regularly spaced bands indicates that MscI sites do not occur at regular intervals. Thus, Lcr1 does not contain exact repeats of our cloned 785-bp unit. (Fig. 6) . Again, this protein is comparable in size to FRA (27) . In contrast, preimmune serum from the same rabbit did not precipitate any proteins, and anti-gp63 precipitated a protein of approximately 60 kDa. Immunoblots of promastigote proteins incubated with serum from immunized BALB/c mice also showed a band of Ͼ200 kDa corresponding to Lcr1 protein, not present in immunoblots incubated with antiserum from unimmunized mice. These immunized mice were challenged with the live organism (next section).
Immunization plete Freund's adjuvant, and challenged with live L. chagasi promastigotes given intravenously. Control mice were immunized with adjuvant alone. After 2 to 10 weeks, groups of four control or immunized mice were sacrificed, and the parasite loads in their livers and spleens were quantified (48) (Fig. 7) . As is typically observed during infection of BALB/c mice, the liver parasite load increased early in infection and spontaneously resolved after 6 to 8 weeks. In contrast, the splenic parasite load began to rise after resolution of hepatic infection. Subcutaneous immunization with Lcr1 caused a statistically significant partial resistance to challenge with the live organism, detected in both the livers and the spleens of infected animals. Immunization of BALB/c mice three times with a higher dose of Lcr1 (100 g) in Ribi adjuvant also protected partially against L. chagasi infection, with (2.03 Ϯ 0.27) ϫ 10 8 amastigotes in control mice and (1.27 Ϯ 0.20) ϫ 10 8 amastigotes in immunized mice 4 weeks after parasite challenge (mean Ϯ standard deviation, P Ͻ 0.05, n ϭ 5). Immunized mice generated antibody to Lcr1 protein, seen on immunoblots of either promastigote lysates (Fig. 6, lane E) or transformed bacterial cells (not shown).
DISCUSSION
This study documents selection of an antigen (Lcr1) from an L. chagasi amastigote cDNA library by using a coupled serum-T-cell screening technique. We used a cDNA library from the amastigote form of the parasite as a source of recombinant protein for study, since the amastigote is the only form present in an infected host. From the fact that it stimulated murine splenic T-cell-enriched cells to secrete the Th1-type cytokine IFN-␥ whereas it failed to stimulate secretion of Th2-type cytokines detectable in our assays (IL-4, IL-5, and IL-10), one would surmise that Lcr1 has the potential to influence disease outcome. Accordingly, immunization with Lcr1 caused partial protection of BALB/c mice against challenge with the live organism. This occurred despite the fact that immunization also elicited antibody production (Fig. 6 , lane E) and therefore was not in the low dose range causing delayed-type hypersensitivity but not an antibody response, as recommended for immunization against L. major (3).
In contrast to findings in murine models of L. major disease, we did not find a correlation between production of either Th1-type (IFN-␥) or Th2-type (IL-5 and IL-10) cytokines and resistance or susceptibility to L. chagasi disease. IL-4 release was detected only in supernatants of T cells from susceptible mice upon exposure to live parasite antigen, although it cannot be determined from this study whether the amount of IL-4 secreted was of immunologic significance. This failure of visceralizing Leishmania species to preferentially induce either a Th1-or Th2-like response correlating with disease outcome has been observed in the past. However, our findings do contrast with a previous study of L. donovani-infected C57BL/10 mice, which documented a correlation between splenocyte IFN-␥ secretion and disease resolution (25) . The source of IFN-␥ secreted in response to Lcr1 cannot be immediately determined from these data. Nonetheless, the ability of IFN-␥ to activate macrophages to kill intracellular leishmaniae, no matter what the cell of origin, could explain the effect of immunization on disease outcome (33) .
There has been considerable interest in antigens stimulating cellular immune responses to Leishmania species because of their potential relevance to disease prevention. Such antigens include the abundant surface glycoprotein gp63 (31, 39) , an antigen associated with the surface glycolipid lipophosphoglycan (41), antigens of 80 (52) and 72 (37) kDa from L. donovani, and 42-and 46-kDa L. amazonensis-derived proteins (4, 8) . Some of these, including the 80-and 72-kDa L. donovani antigens, confer partial protection upon immunization of mice (37, 52) . These antigens were selected by various methods, but none were identified by screening recombinant peptides with splenic T cells as in the case of Lcr1. Using a similar approach, Mustafa and colleagues screened 10,000 randomly selected phage of a Mycobacterium leprae lambda gt11 DNA library with pooled CD4 ϩ T cell clones (35) . Because of the availability of serum that recognizes hundreds of Leishmania antigens, we first immunoscreened our amastigote cDNA library to eliminate clones that do not produce a polypeptide of significant length. The selected peptide-producing clones were subjected to a second screen with T-cell-enriched splenocytes from L. chagasi-infected mice. This double screening approach resulted in the identification of only a small number of clones producing detectable T-cell antigens.
Although this screening strategy was designed to study T-cell responses to a group of proteins as representative of total amastigote antigens as possible, it does omit certain categories of proteins. inated antigens that contain exclusively T-cell epitopes. Second, the successful collection of fusion proteins from medium overlying transformed bacteria relies upon the solubility of these recombinant proteins. Thus, our results contain an inherent bias toward study of soluble and/or secreted proteins. Despite these disadvantages, the approach yielded several antigens that stimulated murine T cells, including Lcr1. The Lcr1 cDNA has significant homology at the amino acid level to a repetitive antigen from T. cruzi (22, 27) . The latter was cloned by two groups from T. cruzi DNA libraries by immunoscreening with infected patient sera (10) . It is similar in size to Lcr1, and it localizes to the inner aspect of the T. cruzi flagellum, hence its designation FRA, for flagellar repeat antigen (27) . Repetitive epitopes have been found in numerous other parasite antigens, often stimulating humoral responses as is the case for both FRA and Lcr1. There are only a few reports of T-cell responses to repetitive peptides (28) , and the response of T cells to FRA has not been studied. It has been suggested that repetitive antigens constitute an immune evasion mechanism through which parasites ''hide'' their more critical antigens, particularly in diseases such as malaria in which a humoral response is important for protective immunity (1). As documented above, immunization with Lcr1 caused partial protection of BALB/c mice against L. chagasi disease, indicating that at least this one repetitive protein does not necessarily provide an immune advantage to the parasite. Whether the nonexact nature of the repeats in Lcr1 influences its capacity to generate B-or T-cell responses is not known.
It has been shown that cloned T cells with opposite biological effects on murine models of cutaneous leishmaniasis utilize the same or similar T-cell receptors (38) . This has led investigators to question the assumption that a particular antigen might elicit either a protective or an exacerbating immune response against L. major (38) . The dose of the antigen (3) and the context or route of antigen delivery (44) may be as important as the actual identity of the antigen in eliciting a protective antiparasite response. If these observations are universal, it is possible that a particular antigen functions merely to provide epitopes that efficiently stimulate T cells but the phenotype of the resultant cellular response is determined by local factors influencing T-cell development. The observation that Lcr1 is recognized by IFN-␥-but not IL-10-producing cells indicates that it is able to induce a protective-type cellular immune response but not necessarily that the response would be protective if the antigen were introduced in another context. Thus, the development of a subunit vaccine may well require delivery of T-cell antigens similar to Lcr1 in the context of adjuvants or delivery systems that bias the local immune response toward IFN-␥ production.
